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Purpose of review  
The purpose of this review is to provide an update on the clinical, public health and economic 
consequences of Campylobacter infection. 
Recent findings 
Campylobacter is a leading bacterial cause of food-related illness. Its importance is enhanced by the 
chronic sequelae that can result from acute infection. Recent advances include a new clinical 
classification system for neurological sequelae with the aim of speeding accurate diagnosis and 
appropriate treatment, a better understanding of the mechanisms underlying post-infectious 
functional gastrointestinal disorders, the emergence of C. concisus and C. showae as potential 
aetiological agents in inflammatory bowel disease, a new mechanism for antimicrobial resistance in 
campylobacters and a better appreciation of the economic costs.  
Summary 
Campylobacter infection is very common and can lead to serious chronic sequelae and considerable 
personal, healthcare and societal costs. 
Key Words 
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irritable bowel syndrome, reactive arthritis 
 
 
  
Page 3 of 21 
 
Abbreviations 
aHR 
aRR 
Bv. 
CI 
DALY 
ELISA  
FGID 
GBS 
HUS 
IBD 
IBS 
IgA 
IgG 
IVIg 
MFS  
MLST 
P-OR 
QoL 
ReA 
RT-PCR 
Subsp.  
  
Page 4 of 21 
 
Introduction 
Since its first identification as a human pathogen in the 1970s Campylobacter has emerged as a 
leading cause of acute gastroenteritis worldwide. Clinically relevant organisms include 
Campylobacter jejuni and C. coli, which are the major pathogens, but several species are recognised 
causes of illness in humans [1•] (Table 1).   
Clinical consequences 
Acute enteritis 
Campylobacter jejuni is among the most frequent causes of bacterial gastroenteritis globally [2-4••].  
Using multilocus sequence typing (MLST) more than 8,300 C. jejuni sequence types (STs) have been 
described [5••]. Although generally considered to cause mild and self-limiting acute enteritis, in a 
recently completed retrospective cohort study in Sweden more than a quarter (27%) of stool culture 
positive Campylobacter cases were admitted to hospital [6•]. The majority (92%) of the laboratory-
confirmed cases were admitted because of severe enteritis or colitis. There was a statistically 
significant 14-fold increase in risk of hospital admission for people with co-morbidities. People 
infected with C. jejuni ST-257 were twice as likely to be admitted to hospital. This study serves as a 
timely reminder that C. jejuni acute enteritis can be severe.   
Chronic sequelae 
As well as causing very unpleasant acute symptoms, Campylobacter infection is also associated with 
various chronic sequelae although the evidence for an association is stronger for some conditions 
than others. Campylobacter infection has been implicated in the subsequent development of 
reactive arthritis (ReA), Guillain-Barré syndrome (GBS) and Miller Fisher syndrome (MFS), haemolytic 
uraemic syndrome (HUS), inflammatory bowel disease (IBD) and functional gastrointestinal disorders 
(FGID). In a recent systematic review and meta-analysis of 31 observational studies the proportion of 
Campylobacter cases developing chronic sequelae was estimated. The proportion of Campylobacter 
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cases that went on to develop ReA was 2.86% (95% CI 1.40% - 5.61%), IBS was 4.01% (95% CI 1.41% - 
10.88%) and GBS was 0.07% (95% CI 0.03%- 0.15%) [7•]. Given the overall incidence of 
Campylobacter infection (see below), these estimates suggest that a considerable number of 
Campylobacter cases can develop chronic sequelae but caution is required when interpreting the 
results because of high heterogeneity between studies. 
Reactive Arthritis 
Reactive arthritis (ReA), formerly known as Reiter’s Syndrome, is a post-infectious spondylo-
arthropathy, which occurs around two to four weeks after gastrointestinal or genitourinary 
infections. The pain associated with ReA occurs most often in the knees, ankles and feet. In a 
systematic review using stringent criteria to define diarrhoea-associated ReA the weighted mean 
incidence of reactive arthritis following Campylobacter infection was 9 per 1,000 cases [8]. Further 
evidence for the contribution of Campylobacter infection to subsequent ReA comes from sero-
prevalence data. Using an optimised ELISA assay for diagnosing a previous Campylobacter infection 
around 53% (44-62%) of ReA cases demonstrated Campylobacter sero-positivity (OMP18 and P39 for 
IgA and in the P39-antigen for IgG) [9]. Polymorphisms in the interleukin-18 and interferon-gamma 
genes appear to be associated with the development of Campylobacter-associated ReA [10]. 
Symptoms of ReA usually disappear completely within six months. However, in 10–20% of people 
the symptoms persist beyond six months although it is said that only a few people develop an 
ongoing arthritis beyond 12 months requiring longer-term treatment. Finally, antibiotic treatment 
does not appear to improve the outcome in ReA [11]. 
Guillain-Barré Syndrome 
The most severe late consequence of Campylobacter infection is Guillain-Barré syndrome (GBS), 
which is the most frequent cause of acute flaccid symmetrical weakness of the limbs and absence of 
deep tendon reflexes [12]. The incidence of post-Campylobacter GBS is estimated to be between 1 in 
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1,000 and 1 in 5,000 cases. It is characterised initially by tingling in the toes, feet and legs, and the 
fingers, hands and arms. This is followed by ascending muscle weakness and paralysis (not to be 
confused with the descending paralysis of botulism). Symptoms of GBS can progress very rapidly. 
The majority of people reach the stage of greatest weakness within the first 2 weeks after symptoms 
first appear, and by the third week 90% of patients are at their weakest. Approximately 30% of 
patients with GBS have persisting weakness after 3 years. Around 3% can experience a relapse of 
muscle weakness and tingling sensations many years after the original episode.  
The heterogeneity of presenting symptoms presents a considerable challenge in the initial clinical 
diagnosis of GBS. In a retrospective review of 69 GBS patients presenting to emergency rooms in 
Texas atypical clinical signs and symptoms led to delayed diagnosis [13].  In that study, neuropathic 
pain and the presence of intact deep tendon reflexes were significantly associated with delayed GBS 
diagnosis. Patients who were assessed by a neurologist during the initial visit experienced 
significantly better clinical outcomes. However, patients in whom GBS was not suspected during the 
initial neurology assessment were significantly more likely to need intubation and to have residual 
weakness at the time of discharge from hospital [13]. 
The mechanism of neural damage involves molecular mimicry between C. jejuni and human 
peripheral nerve proteins [14]. It is known that sialylated lipo-oligosaccharides (LOS) of C. jejuni are 
crucial virulence factors for the development of GBS. However, there is now a suggestion that the 
polysaccharide capsule of C. jejuni is also an important virulence factor [15]. In two geographically 
distinct GBS-associated C. jejuni strain collections researchers concluded that capsular types 
HS1/44c, HS2, HS4c, HS19, HS23/36c and HS41 were markers for GBS compared with controls with 
uncomplicated enteritis [15]. Using MLST they found restricted genetic diversity for strain 
populations with HS2, HS19 and HS41 capsular types. Thus these capsules may also confer 
susceptibility to GBS. 
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Management of GBS involves plasmapheresis and high-dose immunoglobulin therapy plus 
supportive treatment e.g. mechanical ventilation, prevention of complications such as pneumonia or 
bed sores and physiotherapy as muscle strength returns.  In a Cochrane systematic review of six 
randomised controlled trials plasmapheresis was found to help speed recovery from GBS without 
causing significant harm [16]. The authors concluded that there was moderate-quality evidence 
showing significantly greater improvement with plasmapheresis than supportive care alone in adults 
with Guillain-Barré syndrome without a significant increase in serious adverse events. They found a 
small but significant increase in the risk of relapse during the first six to 12 months after onset in 
patients treated with plasmapheresis exchange compared with patients not undergoing this 
treatment. Nevertheless, after 12 months, patients who had undergone plasmapheresis were 
significantly more likely to recover fully and were less likely to suffer severe residual weakness [16]. 
More recently in a Cochrane review of 12 trials there was moderate quality evidence that, in severe 
disease, starting intravenous immunoglobulin (IVIg) started two weeks from onset hastened 
recovery as much as plasmapheresis [17]. There was also moderate quality evidence that 
administering IVIg after plasmapheresis did not afford significant additional advantage [17]. Finally, 
often overlooked features of GBS are fatigue, pain and psychological distress, which can have a 
considerable impact on health-related quality of life (QoL) [18•]. 
Miller Fisher Syndrome  
Miller Fisher syndrome (MFS) is a rare late consequence of Campylobacter infection. Essentially, it is 
a non-paralytic variant of GBS in which patients present with ophthalmoplegia, ataxia and areflexia. 
Recently a new, simple, clinical classification system has been proposed for GBS, MFS and their sub-
types to help to facilitate early clinical diagnosis with a view to starting appropriate immunotherapy 
as rapidly as possible [19••]. 
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Haemolytic Uraemic Syndrome 
Antecedent Campylobacter infection has been associated with diarrhoea-related HUS. It is believed 
to be a rare cause of pulmonary-renal syndrome leading to life-threatening pulmonary haemorrhage 
[20]. 
Inflammatory Bowel Disease 
There has been considerable debate over the years about a role for Campylobacter infection in the 
aetiology of inflammatory bowel disease (IBD). It has been postulated that in genetically predisposed 
people gut microbes, in association with a disrupted gastrointestinal epithelium, can fuel and then 
drive a dysregulated immune response that results in chronic inflammation in the intestine [21,22•]. 
In a recent systematic review and meta-analysis the association between IBD and a variety of 
Campylobacter spp. was investigated [23••]. In total the sample comprised 519 patients with IBD 
and 1,133 non-IBD controls. Overall there was an almost three-fold increase in risk of IBD following 
infection with Campylobacter spp. (pooled odds ratio (P-OR) = 2.97 (95% confidence interval (CI) 
1.33 - 6.63, p =0.008). In that review Campylobacter spp. were confirmed in 39% of patients with IBD 
compared with 13% of non-IBD controls. On stratification by Campylobacter spp. the analyses 
showed that the organisms chiefly responsible for the observed association with increased risk of 
IBD were C. concisus (P-OR: 3.76, 95% CI 1.46 to 9.70, p value=0.006) and C. showae (P-OR: 2.39, 
95% CI 1.11 - 5.18, p =0.027) [23••].  
Functional Gastrointestinal Disorders 
The link between acute gastroenteritis and subsequent post-infectious irritable bowel syndrome 
(IBS) has been established for some time but there are few studies which have quantified pathogen-
specific risk. In a retrospective cohort study of FGID amongst the US military there were statistically 
significant associations between antecedent Campylobacter infection and the risk of developing 
post-infectious IBS (Adjusted relative risk (aRR) = 2.8 (95% CI 1.9 - 4.1), functional dyspepsia (aRR = 
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2.0 (95% CI 1.3 - 3.0), functional constipation (aRR = 1.8 (95% CI 1.3 - 2.5) and gastro-oesophageal 
reflux disease (aRR = 1.7 (95% CI = 1.4 - 2.1) [24••]. In a prospective study risk factors for new-onset 
irritable bowel syndrome (IBS) among active personnel enrolled in the US military's Millennium 
Cohort Study significant risk factors included preceding acute gastroenteritis (adjusted hazard ratio 
(aHR) = 2.05 (95% CI = 1.53 – 2.75), female sex (aHR = 1.96 (95% CI =  1.53 –2.52) and anxiety 
syndrome (aHR = 1.74 (95% CI = 1.17 – 2.58)). There was also a dose-response relationship with 
number of life stressors (1 stressor: aHR = 1.82 (95% CI =  1.37–2.41); 2 stressors: (aHR = 2.86 (95% 
CI = 2.01 –4.06 ); 3 or more stressors: (aHR = 6.69 (95% CI = 4.59 – 9.77. Pre-existing anxiety or 
depression and acute gastroenteritis interacted with increased IBS risk compared with acute 
gastreonteritis alone [25••]. The complex interplay between intestinal microbiota and the 
autonomous nervous system (the so-called “gut-brain axis”) in conjunction with the immune system 
suggest that the gut-brain axis has a central function in perpetuating irritable bowel syndrome and 
that the intestinal microbiota play a critical part [26••].  
Links between acute gastroenteritis (including Campylobacter infection) and FGID other than IBS are 
also gaining recognition. For example, there is a statistically significant association between 
functional dyspepsia and preceding acute gastroenteritis (summary odds ratio for post-infectious 
functional dyspepsia = 2.54 (95% CI = 1.76–3.65) [27•].  
 
Public Health Consequences 
Illness burden 
The population burden of illness associated with Campylobacter infection is very high. On a global 
scale Campylobacter spp. are estimated to cause some 96 million (95% uncertainty interval (UI) 52 - 
177 million) cases of foodborne illness [4••]. In the UK there are some 280,000 cases of 
Campylobacter foodborne illness [28] whilst in Canada the estimate is around 145,000 cases [29]. 
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An increasingly common metric for describing the burden of disease associated with foodborne 
pathogens is the disability-adjusted life year (DALY), which is a useful method for combining loss of 
life and health due to illness compared with a “perfect” state of health, using time as the common 
measure. In the US Campylobacter infection is estimated to cause about 22 500 DALYs annually [30], 
whilst in the Netherlands Campylobacter spp. are responsible for around 3,600 DALYs per year [31]. 
Outbreaks 
The association between eating undercooked poultry and developing Campylobacter infection is well 
known. However, consuming lightly cooked chicken livers, chicken liver pâté and chicken liver parfait 
has emerged as important risk factors [32-34]. Recognising this emerging trend in the UK, the Food 
Standards Agency commissioned research to develop a recipe for manufacturing commercial 
quantities of chicken liver pâté that reliably kills campylobacters [35•]. Further evidence that 
cooking practices are responsible for Campylobacter cases and outbreaks associated with lightly 
cooked chicken livers comes from an interdisciplinary study in the UK [36•]. In an online survey most 
chefs who took part could correctly identify safely cooked chicken livers. However they tended to 
overestimate consumers’ preference for “pinkness” and so chefs tended to serve chicken livers more 
lightly cooked than the public would have preferred. Moreover it was estimated that 19%-52% of 
livers served commercially in the UK do not reach the recommended cooking temperature of 70°C 
and that predicted Campylobacter survival rates in those undercooked livers were between 48% and 
98% [36•]. More esoteric causes of recent outbreaks have included contact with wildlife [37], and 
consumption of raw milk (either intentionally or through failure of pasteurisation) continues to pose 
risks for Campylobacter infection [38,39•]. 
Sporadic infection 
The majority of Campylobacter cases are unrelated to outbreaks. Newly identified risk factors for 
sporadic in recently published case-control studies include contact with garden soil for C. jejuni and 
C. coli, and consuming beef (C. coli only) [40], and eating cantaloupe and queso fresco (Mexican 
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cheese) [41]. However, consumption of contaminated poultry continues to feature prominently in 
the epidemiology of sporadic cases [42,43]. This is not necessarily surprising given the continued 
high prevalence of contamination of poultry on retail sale [44].  
Antimicrobial resistance 
Fluoroquinolone and macrolide resistance are well established in campylobacters. Recently a new 
mechanism for enhanced multidrug resistance in campylobacters has been discovered, which 
confers remarkably high-level resistance to fluoroquinolones [45••]. This involves the emergence of 
so-called "super" efflux pump variants that enhance resistance to multiple antimicrobials.  This is a 
resistance-enhancing variant (so-called RE-CmeABC) of the predominant Campylobacter efflux pump 
CmeABC. It also seems that RE-CmeABC can be transferred horizontally [45••]. 
 
Economic consequences 
Various researchers have monetised the cost of Campylobacter infection (Table 2). The estimates of 
cost vary quite widely reflecting differences in, for example, study design, costing elements included 
and type of healthcare system. Some researchers included in their cost estimates the impact of long 
term sequelae whilst others did not. Despite the differences in study design the broad message is 
the same – namely that Campylobacter is a costly infection.  
The likely costs of prevention can be hard to estimate but point to the fact that whilst the savings 
from prevention would accrue mainly to cases and health services the costs would lie elsewhere in 
government and in industry. Nevertheless in New Zealand, where there has been a considerable 
effort to reduce Campylobacter contamination of poultry flocks the benefit:cost ratio was extremely 
high [50••]. The beneficial effect of reduced campylobacteriosis to the New Zealand economy was 
around NZD 57 million per year. So investing in food safety compliance measures at primary 
production was very worthwhile [50••]. In the absence of such measures in other countries 
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preventing Campylobacter infection still relies on the so-called “4Cs”- thorough cooking and cleaning 
(including hands and work surfaces), proper chilling and avoiding cross-contamination. 
Conclusions 
Campylobacter causes considerable morbidity worldwide. Post-infectious sequelae mainly affect the 
gastrointestinal tract (FGID, IBD), the musculoskeletal system (ReA) and the peripheral nervous 
system (GBS, MFS) and these sequelae can lead to lifelong disability and reduction in health-related 
quality of life. The economic costs of Campylobacter infection are very high for cases, the healthcare 
system and for society in general. However, in general, prevention still depends on tried and tested 
methods i.e. good food (and personal) hygiene. 
Key points  
• Campylobacter is one of the leading bacterial foodborne pathogens worldwide. 
• Chronic sequelae post Campylobacter infection can be very serious, causing considerable lifelong 
morbidity. 
• There is growing evidence of the importance of the interaction of the gut-brain axis, microbiota 
and immune system in the pathogenesis of irritable bowel syndrome. 
• C. concisus and C. showae are emerging as potentially important triggers of inflammatory bowel 
disease. 
• Preventing Campylobacter infection still relies on the so-called “4Cs”- thorough cooking and 
cleaning (including hands and work surfaces), proper chilling and avoiding cross-contamination. 
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Table 1: Summary of clinically relevant Campylobacter species [1] 
Campylobacter species Clinical Features/Associations Reservoir(s) 
C. coli Gastroenteritis, septicaemia Dogs, cattle, pigs 
C. concisus Gastroenteritis, periodontal 
disease, septicaemia; associated 
with inflammatory bowel disease, 
Barrett’s oesophagus 
Humans, dogs, cats 
C. curvus Abscess, gastroenteritis  Humans 
C. fetus subspecies 
(subsp.) fetus 
Meningitis, septicaemia, foetal 
loss, vascular infection 
Cattle, dogs, sheep, 
turtles 
C. fetus subsp. 
venerealis 
Septicaemia Cattle 
C. gracilis Abscess Dogs, humans 
C. hyointestinalis 
subsp. 
hyointestinalis 
Gastroenteritis, septicaemia Cattle, hamsters, pigs  
C. insulaenigrae Gastroenteritis, septicaemia Porpoises, seals  
C. jejuni subsp. jejuni Gastroenteritis, septicaemia, 
foetal loss, mesenteric adenitis, 
colitis, myocarditis, reactive 
arthritis,  
Guillain-Barré syndrome, Miller 
Fisher syndrome 
Cattle, dogs, poultry, 
sheep, wild birds  
C. jejuni subsp. doylei Gastroenteritis, septicaemia Humans, dogs 
C. lari subsp. lari Gastroenteritis, septicaemia Cats, dogs, chickens, seals 
C. rectus Abscess Humans 
C. showae Septicaemia, cholangitis; 
associated with inflammatory 
bowel disease 
Humans, dogs 
C. sputorum biovar 
(bv.) sputorum 
Abscess Humans, cattle, pigs, 
sheep 
C. upsaliensis Enteritis, septicemia, abortion, 
abscesses 
Cats, dogs, ducks, 
monkeys 
C. ureolyticus Associated with ulcerative colitis Cattle 
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Table 2: Summary of recently published studies estimating the monetary costs of Campylobacter 
infection 
Country Year Estimated Annual Cost  Estimated cost per case 
UK [46] 2008-9 GBP 50 million  GBP 85 
Netherlands [47] 2011 EUR 76 million EUR 706 
Switzerland [48] 2012-14 EUR 29–45 million EUR 63–95 
US [49] 2013 USD 1.9 billion USD 2,283 
 
 
